How AI is Transforming Biopharma's Future
Greg Meyers, the Chief Digital and Technology Officer at Bristol Myers Squibb (BMS), discussed how artificial intelligence (AI) is revolutionizing the biopharmaceutical industry. He emphasizes that today's technology isn't just about enhancing efficiency; it’s about creating new ways to make treatments more effective and accessible for patients.
The Journey to Leadership in Technology
Meyers's journey started with an early fascination with computers when he was just 12 years old. His experiences have shaped his belief that technology should drive innovation in pharmaceuticals. When he joined BMS, his goal was to reinvigorate the company’s technology function and place it back at the forefront of creating new solutions.
Putting the 'T' Back in IT
Recognizing the shift from merely maintaining systems to actively building advanced technological solutions, Meyers prioritized a cultural transformation at BMS. “We wanted to be creators rather than just service brokers,” he explained, leading to a doubling of the technology team. This increase in headcount has allowed BMS to refocus on developing solutions internally, enhancing their capacity to innovate.
A Diverse Background Fuels Innovation
Greg’s diverse experiences across several industries, including agriculture and consulting, have contributed to his effectiveness at BMS. He argues that the core challenges remain constant across sectors: using technology to gain a competitive edge. In biopharma, marrying computer science with traditional biological and chemical sciences is key to fostering innovation and delivering better patient outcomes.
The Evolution of AI: A Vital Tool
As AI continues to evolve, it’s becoming integrated into the very fabric of drug development. Meyers states that this integration allows researchers to experiment more freely and ultimately deliver treatments that are better tailored to individual patient needs. Innovation rooted in technology sets the foundation for a future where health solutions can be more precise and impactful.
A Vision for the Future
Looking ahead, Meyers sees a landscape where technology and R&D continuously interlink. By advancing the convergence of computer science, biology, and chemistry, the biopharma sector will be better equipped to tackle tomorrow's health challenges. The stakes are higher than ever, but so are the opportunities for making significant strides in patient care.
Add Row
Add
Write A Comment